Sionna Therapeutics halts SION-719 add-on program after Phase 2a PreciSION CF trial fails key sweat chloride endpoint
- Company will not advance SION-719 as an add-on therapy to Trikafta following Phase 2a results
- Sionna is evaluating next steps for its SION-451 dual-combination program and planning capital-preservation measures
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.